Cargando…
The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice
INTRODUCTION: Cognitive impairment in multiple sclerosis (MS) is common even in the early stages of the disease. Our objective was to improve early detection of cognitive impairment in MS. METHODS: Seventy-five patients with relapsing remitting (RR) MS and 20 controls were enrolled. Two RRMS groups...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386426/ https://www.ncbi.nlm.nih.gov/pubmed/26000227 http://dx.doi.org/10.1007/s40120-014-0021-x |
_version_ | 1782365177564364800 |
---|---|
author | Laffon, Muriel Malandain, Grégoire Joly, Heloise Cohen, Mikael Lebrun, Christine |
author_facet | Laffon, Muriel Malandain, Grégoire Joly, Heloise Cohen, Mikael Lebrun, Christine |
author_sort | Laffon, Muriel |
collection | PubMed |
description | INTRODUCTION: Cognitive impairment in multiple sclerosis (MS) is common even in the early stages of the disease. Our objective was to improve early detection of cognitive impairment in MS. METHODS: Seventy-five patients with relapsing remitting (RR) MS and 20 controls were enrolled. Two RRMS groups were defined according to their results at the Paced Auditory Serial Addition Test (PASAT). Patients with a z score below two standard deviations were considered impaired. We quantified T2 and T1 lesion volumes, and cerebral white and grey matter volumes on a conventional brain magnetic resonance imaging (MRI) scan. Global brain atrophy was evaluated using the third ventricle (V3) width (in mm). An average brain model was built based on controls and compared with the patient’s MRI to quantify regional volumetric changes. RESULTS: Sixteen (21.3%) patients with RRMS had low PASAT performance. They had a higher Expanded Disability Status Scale (EDSS) score (P = 0.019). T2 and T1 lesion volumes, and grey and white matter volumes were the same in both groups. An enlargement of the V3 width was observed in the low performer group (P = 0.044) and V3 width was correlated with the PASAT score (r = −0.271; P = 0.021). A composite score, named HV3, was obtained by adding the EDSS and V3 width (in mm) and correlated with the PASAT (r = −0.325; P = 0.006). A cutoff HV3 score of over 5.5 identified patients with low PASAT performance, with a positive predictive value of 92.5% and an accuracy of 70.1%. Focal atrophy was detected in the supplementary motor area, the cingulate gyrus, the right thalamus, and the inferior parietal lobules of patients with lower PASAT performance. CONCLUSION: Specific brain morphological changes, including an enlargement of the V3 width, are associated with low PASAT performance in patients with RRMS. The HV3 score is an additional and complementary tool, accessible in clinical practice, to suspect easily cognitive impairment in patients with RRMS and to better identify patients requiring a complete cognitive assessment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40120-014-0021-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4386426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-43864262015-05-21 The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice Laffon, Muriel Malandain, Grégoire Joly, Heloise Cohen, Mikael Lebrun, Christine Neurol Ther Original Research INTRODUCTION: Cognitive impairment in multiple sclerosis (MS) is common even in the early stages of the disease. Our objective was to improve early detection of cognitive impairment in MS. METHODS: Seventy-five patients with relapsing remitting (RR) MS and 20 controls were enrolled. Two RRMS groups were defined according to their results at the Paced Auditory Serial Addition Test (PASAT). Patients with a z score below two standard deviations were considered impaired. We quantified T2 and T1 lesion volumes, and cerebral white and grey matter volumes on a conventional brain magnetic resonance imaging (MRI) scan. Global brain atrophy was evaluated using the third ventricle (V3) width (in mm). An average brain model was built based on controls and compared with the patient’s MRI to quantify regional volumetric changes. RESULTS: Sixteen (21.3%) patients with RRMS had low PASAT performance. They had a higher Expanded Disability Status Scale (EDSS) score (P = 0.019). T2 and T1 lesion volumes, and grey and white matter volumes were the same in both groups. An enlargement of the V3 width was observed in the low performer group (P = 0.044) and V3 width was correlated with the PASAT score (r = −0.271; P = 0.021). A composite score, named HV3, was obtained by adding the EDSS and V3 width (in mm) and correlated with the PASAT (r = −0.325; P = 0.006). A cutoff HV3 score of over 5.5 identified patients with low PASAT performance, with a positive predictive value of 92.5% and an accuracy of 70.1%. Focal atrophy was detected in the supplementary motor area, the cingulate gyrus, the right thalamus, and the inferior parietal lobules of patients with lower PASAT performance. CONCLUSION: Specific brain morphological changes, including an enlargement of the V3 width, are associated with low PASAT performance in patients with RRMS. The HV3 score is an additional and complementary tool, accessible in clinical practice, to suspect easily cognitive impairment in patients with RRMS and to better identify patients requiring a complete cognitive assessment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40120-014-0021-x) contains supplementary material, which is available to authorized users. Springer Healthcare 2014-11-25 /pmc/articles/PMC4386426/ /pubmed/26000227 http://dx.doi.org/10.1007/s40120-014-0021-x Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Laffon, Muriel Malandain, Grégoire Joly, Heloise Cohen, Mikael Lebrun, Christine The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice |
title | The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice |
title_full | The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice |
title_fullStr | The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice |
title_full_unstemmed | The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice |
title_short | The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice |
title_sort | hv3 score: a new simple tool to suspect cognitive impairment in multiple sclerosis in clinical practice |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386426/ https://www.ncbi.nlm.nih.gov/pubmed/26000227 http://dx.doi.org/10.1007/s40120-014-0021-x |
work_keys_str_mv | AT laffonmuriel thehv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT malandaingregoire thehv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT jolyheloise thehv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT cohenmikael thehv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT lebrunchristine thehv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT laffonmuriel hv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT malandaingregoire hv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT jolyheloise hv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT cohenmikael hv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice AT lebrunchristine hv3scoreanewsimpletooltosuspectcognitiveimpairmentinmultiplesclerosisinclinicalpractice |